Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: A case series

Journal of Child and Adolescent Psychopharmacology

Volumn 15, Issue 4, 2005, Pages 696-702

  Pathak, Sanjeev ^a,b   Johns, Erin S ^a   Kowatch, Robert A ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; CANNABIS; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; NORTRIPTYLINE; PAROXETINE; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADOLESCENT; ADULT; ANOREXIA NERVOSA; ARTICLE; ATTENTION DEFICIT DISORDER; AUTOMUTILATION; CANNABIS ADDICTION; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COMORBIDITY; CONTROLLED STUDY; DISEASE DURATION; DROWSINESS; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENERALIZED ANXIETY DISORDER; GILLES DE LA TOURETTE SYNDROME; HUMAN; MAJOR DEPRESSION; MALE; SEDATION; SIDE EFFECT; SOCIAL PHOBIA; SUICIDE ATTEMPT; TRICHOTILLOMANIA; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; WEIGHT GAIN;

EID: 26444438152     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2005.15.696     Document Type: Article

References (29)

1. Adson D, Kushner M, Eiben K, Schulz S: Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety 19:121-126, 2004.
2. Angola A, Messer SC, Stangl D, Farmer EM, Costello EJ, Burns BJ: Perceived parental burden and service use for child and adolescent psychiatric disorders. Am J Public Health 88:75-80, 1998.
3. Birmaher B, Brent D, Benson R: Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 37:1234-1238, 1998.
4. Boehm G, Racoosin J, Laughren T, Katz R: Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes: Response to consensus statement. Diabetes Care 27:2088-2089, 2004.
5. Brent DA, Birmaher B: British warnings on SSRIs questioned. J Am Acad Child Adolesc Psychiatry 43:379-380, 2004.
6. Delbello MP, Schwiers ML, Rosenberg HL, Strakowski SM: A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 41:1216-1223, 2002.
7. Dietz WH: Health consequences of obesity in youth: Childhood predictors of adult disease. Pediatrics 101:518-525, 1998.
8. Doree JP, Tourjman SV, Kunicki S, Desrosiers J, Vanier C, Elie R, Lew VA: Comparison of Quetiapine Versus Lithium Treatment of Resistant Depression, [abstract] New York, American Psychiatric Association, 2004.
9. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, Nilsson M, Jacobson JG: Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41:1205-15, 2002.
10. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, Rintelmann J: A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 54:1031-1037, 1997.
11. Entsuah AR, Huang H, Thase ME: Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 62:869-877, 2001.
12. Fleming JE, Offord DR: Epidemiology of childhood depressive disorders: A critical review. J Am Acad Child Adolesc Psychiatry 29:571-580, 1990.
13. Guy W: ECDEU Assessment Manual for Psychopharmacology. Rockville, (MD), U.S. Department of Health, Education, and Welfare publciation (ADM), 1976.
14. Kashani JH, Carlson GA, Beck NC, Hoeper EW, Corcoran CM, McAllister JA, Fallahi C, Rosenberg TK, Reid JC: Depression, depressive symptoms, and depressed mood among a community sample of adolescents. Am J Psychiatry 144:931-934, 1987.
15. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988, 1997.
16. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, Hagino OR, Koplewicz H, Carlson GA, Clarke GN, Emslie GJ, Feinberg D, Geller B, Kusumakar V, Papatheodorou G, Sack WH, Sweeney M, Wagner KD, Weller EB, Winters NC, Oakes R, McCafferty JP: Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 40:762-772, 2001.
17. Kennedy S, McIntyre R, Fallu A, Lam R: Pharmacotherapy to sustain the fully remitted state. J Psychiatry Neurosci 27:269-280, 2002.
18. Koplewicz HS: Misguided resistance to appropriate treatment for adolescent depression. J Child Adolesc Psychopharmacol 14:vii, 2004.
19. Lewinsohn PM, Hops H, Roberts RE, Seeley JR, Andrews JA: Adolescent psychopathology: I. Prevalence and incidence of depression and other DSM-III-R disorders in high school students. J Abnorm Psychol 102:133-144, 1993.
20. Masand P, Mago R, Patkar A, Peindl K, Purcell C: An Open-Label, Rater-Blinded Study of Aripiprazole as an Augmenting Agent in Patients with Treatment-Resistant Depression, [abstract] Phoenix, (AZ), NCDEU, 2004.
21. Rapaport M, Canuso C, Rouillon R, Leblanc J, Young A, Loescher A, Bossie C, Turkoz I, Gharabawi G: Results From the Augmentation with Risperidone in Resistant Depression Trial, [abstract] New York, American Psychiatric Association, 2004.
22. Rudolph RL, Feiger AD: A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 56:171-181, 1999.
23. Sajatovic M, Mullen JA, Sweitzer DE: Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry 63:1156-1163, 2002.
24. Shaffer D, Gould MS, Fisher P, Trautman P, Moreau D, Kleinman M, Flory M: Psychiatric diagnosis in child and adolescent suicide. Arch Gen Psychiatry 53:339-348, 1996.
25. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY: A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 158:131-134, 2001.
26. Thase ME, Entsuah AR, Rudolph RL: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234-241, 2001.
27. Treatment for Adolescents with Depression Study Team: Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA 292:807-820, 2004.
28. Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS, Childress A, Donnelly C, Deas D: Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: Two randomized controlled trials. JAMA 290:1033-1041, 2003.
29. Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE: A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 161:1079-1083, 2004.